Clinical Trial Update: A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC [Phase 1]

View source ↗

Summary

A Phase 1 study of MT-303 in adults with advanced or metastatic GPC3-expressing cancers, including hepatocellular carcinoma, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MT-303

Snippet

Sponsor: Myeloid Therapeutics | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING